Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Raffaele De Caterina, Walter Ageno, Giuseppe Boriani, Paolo Colonna, Angelo Ghirarduzzi, Giuseppe Patti, Roberta Rossini, Andrea Rubboli, Piercarla Schinco, Giancarlo Agnelli

Research output: Contribution to journalArticle

Abstract

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalAdvances in Therapy
DOIs
Publication statusAccepted/In press - Feb 13 2017
Externally publishedYes

    Fingerprint

Keywords

  • Atrial fibrillation
  • Edoxaban
  • Non-vitamin K antagonist oral anticoagulants
  • Oral anticoagulants
  • Venous thromboembolism
  • Vitamin K antagonists

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Caterina, R. D., Ageno, W., Boriani, G., Colonna, P., Ghirarduzzi, A., Patti, G., Rossini, R., Rubboli, A., Schinco, P., & Agnelli, G. (Accepted/In press). Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide. Advances in Therapy, 1-18. https://doi.org/10.1007/s12325-017-0488-9